Industry News

IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. today announced key senior management roles in the future Quintiles IMS corporate leadership team, subject to the completion of the merger. Senior functional leaders reporting to Chairman and Chief Executive Officer Ari Bousbib will include Michael McDonnell, EVP and Chief Financial Officer; James Erlinger, EVP and General Counsel; and Trudy Stein, EVP and Chief..."/>
IMS Health and Quintiles Announce Key Officers for Merged Company
IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. today announced key senior management roles in the future Quintiles IMS corporate leadership team, subject to the completion of the merger. Senior functional leaders reporting to Chairman and Chief Executive Officer Ari Bousbib will include Michael McDonnell, EVP and Chief Financial Officer; James Erlinger, EVP and General Counsel; and Trudy Stein, EVP and Chief..."/>
IMS Health and Quintiles Announce Key Officers for Merged Company
Canopy Growth Corporation today released its financial results for the first quarter fiscal 2017 ended June 30, 2016. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. Consolidated financial results include the accounts of the Company and its wholly? owned subsidiaries Tweed Inc., Tweed Farms..."/>
Canopy Growth Reports First Quarter Fiscal 2017 Financial Results
Innovus Pharmaceuticals, Inc., an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men's and women's health and respiratory diseases, today announced today that Mr. Robert Hoffman will join..."/>
With Revenues Climbing, Innovus Pharma Adds Robert E. Hoffman as its Chief Financial Officer
OraSure Technologies, Inc. announced today that a study conducted by Human Longevity, Inc. and published in the Journal Scientific Reports on August 25, 2016 proposes the use of the OMNIgene• GUT microbiome sample collection and stabilization device sold by OraSure’ s wholly-owned subsidiary, DNA Genotek Inc., in global microbiome studies. The published report can be found online at http://www.nature.com/articles/srep31731.."/>
DNA Genotek’s OMNIgene®? GUT Kit is Proposed as Standardized Test for Worldwide Studies of the Human Microbiome
Cynapsus Therapeutics Inc., today announced that the U.S. Food and Drug Administration has granted Fast Track Designation for APL-130277, a product candidate for the treatment of OFF episodes in patients with Parkinson’ s disease.. “The FDA’ s recognition of the significant need to address OFF episodes in Parkinson’ s disease with the Fast Track Designation is further validation of the value in our fast-acting, thin strip approach,” said Anthony Giovinazzo,..."/>
Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease
Cynapsus Therapeutics Inc., today announced that the U.S. Food and Drug Administration has granted Fast Track Designation for APL-130277, a product candidate for the treatment of OFF episodes in patients with Parkinson's disease. "The FDA's recognition of the significant need to address OFF episodes in Parkinson's disease with the Fast Track Designation is further validation of the value in our fast-acting, thin strip..."/>
Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
CTI BioPharma Corp. today announced top-line results from PERSIST-2, a randomized, controlled Phase 3 clinical trial comparing pacritinib, an investigational oral multikinase inhibitor, with physician-specified best available therapy, including ruxolitinib, for the treatment of patients with myelofibrosis whose platelet counts are less than 100,000 per microliter-- a patient population with high-risk advanced disease."/>
CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis
Amgen today announced data presented at the European Society of Cardiology Congress 2016 showing Repatha ® consistently reduced low-density lipoprotein cholesterol in patients across cardiovascular risk subgroups or with familial hypercholesterolemia. "These analyses continue to shape the clinical evidence for Repatha and help to advance our understanding of its potential to benefit patients," said Sean E. Harper, M.D.,..."/>
New Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016
Regeneron Pharmaceuticals, Inc. and Sanofi today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent ® Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by..."/>
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
VF Corp. has closed the sale of its contemporary brands businesses to Israel-based apparel maker and marketer Delta Galil Industries, Ltd for USD120m, the company said."/>
M and A Navigator: Deal pipeline –29 August
Macrocure Ltd. has signed a merger agreement to become a wholly owned subsidiary of clinical stage immuno-oncology company Leap Therapeutics, the company said. In connection with the transaction, Leap will apply to have the shares of the combined entity listed for trading on NASDAQ upon completion of the merger. Under the terms of the agreement, Macrocure shareholders will exchange their Macrocure shares for newly issued..."/>
Israeli Biotech Firm Macrocure to Merge with Immuno-Oncology Specialist Leap Therapeutics
LivaNova's exclusive SonR sensor-based CRT optimization system.. LONDON, Aug. 28, 2016-- LivaNova PLC, a market-leading medical technology company, today announced long term results from the RESPOND-CRT clinical trial after an 18 month follow-up period. The results were presented by the principal investigator, Prof."/>
SonR(TM): Long Term Clinical Update Confirms Risk Reduction in Heart Failure Hospitalization
LivaNova PLC, a market-leading medical technology company, today announced long term results from the RESPOND-CRT clinical trial after an 18 month follow-up period. The results were presented by the principal investigator, Prof. Josep Brugada, at an oral Clinical Trial Update session during the annual European Society of Cardiology meeting."/>
SonR™: Long Term Clinical Update Confirms Risk Reduction in Heart Failure Hospitalization
Daily Mail, London, market report column [Daily Mail, London]
Mylan NV up to $100 million, but calculating the damage to the pharmaceutical company's reputation from its controversial price hikes may be more difficult. Mylan found itself at the center of a storm this week as a burst of outrage over a more than 500 percent increase in the price of EpiPen since 2007 forced the company to offer subsidies to cut out-of-pocket costs for some patients buying the life-saving allergy drug."/>
Mylan reputation at stake in EpiPen controversy [The Pittsburgh Tribune-Review]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary544 Articles
Information Technology475 Articles
Financials413 Articles
Industrials289 Articles
Health Care282 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.